Status:
COMPLETED
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Lead Sponsor:
Gilead Sciences
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
Detailed Description
This is a first-in-human, first-in-class, escalating dose trial of an antibody that inhibits an anti-apoptotic signal in human macrophages. The major aims of the study are to define the safety profile...
Eligibility Criteria
Inclusion
- Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma
- Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment.
- Adequate hematologic status
- Adequate coagulation function
- Adequate hepatic function
- Adequate renal function
Exclusion
- Known primary tumors of central nervous system disease
- Known active brain metastases
- Known cardiopulmonary disease
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT02216409
Start Date
August 1 2014
End Date
December 1 2018
Last Update
February 5 2019
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Cancer Institute
Stanford, California, United States, 94305
2
University of Chicago
Chicago, Illinois, United States, 60637
3
START Midwest
Grand Rapids, Michigan, United States, 49503
4
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065